^
Association details:
| Biomarker: | BRAF V600 |
|---|---|
| Cancer: | Colorectal Cancer |
| Drug: | dactolisib (RTB101) (mTOR inhibitor, PI3K inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Inhibition of MEK and PI3K/mTOR Suppresses Tumor Growth but Does Not Cause Tumor Regression in Patient-Derived Xenografts of RAS-Mutant Colorectal Carcinomas
Excerpt:
Forty mCRC specimens harboring KRAS, NRAS, BRAF, and/or PIK3CA mutations were implanted in nonobese diabetic/severe combined immunodeficient (NOD/SCID) mice....When correlating such drug sensitivity subgroups to the distribution of mutant genotypes, we found that the 3 BRAF codon 600 mutant tumors seem to be poorly sensitive to MEK inhibition and all segregated in the subset that showed preferential responsiveness to BEZ235.
DOI:
10.1158/1078-0432.CCR-11-2683
